Chandigarh, Mar 19 : Pharma Major Dr Reddy's Labs on Thursday announced the launch of Naloxone Hydrochloride Injection USP, 2 mg/2 ml (1 mg/ml) Single-dose Prefilled Syringe, a therapeutic equivalent generic version of Narcan (naloxone hydrochloride) Injection USP, approved by the US Food and Drug Administration (USFDA).
"We are pleased to bring our second product to market that has been designated as a Competitive Generic Therapy (CGT) by the USFDA," said Marc Kikuchi, Chief Executive Officer of North America Generics, Dr Reddy's Laboratories.
"With a CGT designation, we have 180-day CGT exclusivity to market this product," he added. The Naloxone Hydrochloride Injection USP, 2 mg/2 ml (1 mg/ml) had US sales of around USD31 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health. Dr Reddy's Naloxone Hydrochloride Injection USP, 2 mg/2 ml (1 mg/ml) is available in 2 ml single-dose prefilled syringe. (UNI)